Site Editors

Shaji K. Kumar, MD

Prashant Kapoor, MD, FACP

Advertisement
Advertisement

Triple-Class–Exposed Patients With Myeloma: Ciltacabtagene Autoleucel Versus Real-World Therapies

By: Kayci Reyer
Posted: Friday, August 5, 2022

Findings from the phase Ib/II CARTITUDE-1 study, published in Clinical Lymphoma, Myeloma, & Leukemia, suggest that treatment with ciltacabtagene autoleucel may result in substantially improved survival outcomes versus real-world therapies among some patients with relapsed or refractory multiple myeloma. This anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy previously demonstrated efficacy among patients with multiple myeloma who were triple-class–exposed, having received immunomodulatory, proteasome inhibitor, and anti-CD38 monoclonal antibody treatments.

“These findings suggest ciltacabtagene autoleucel may represent a useful treatment option compared with currently available therapies for this patient population with a high unmet need,” concluded Luciano J. Costa, MD, PhD, of the University of Alabama at Birmingham; Shaji Kumar, MD, of the Mayo Clinic, Rochester, Minnesota; and colleagues.

The study used the MAMMOTH data set of patients who were refractory to anti-CD38 monoclonal antibody treatment to identify eligible patients. Enrolled patients in the intent-to-treat population (n = 113) had undergone apheresis; those in the modified intent-to-treat population (n = 97) received ciltacabtagene autoleucel. Corresponding sets of patients were also identified, with 190 in the MAMMOTH intent-to-treat population and 122 in the modified intent-to-treat population. The modified group was defined as having experienced neither disease progression nor death within 47 days of treatment initiation. Overall, 95 and 69 patients from the CARTITUDE-1 intent-to-treat and modified intent-to-treat populations, respectively, were matched with patients from the corresponding MAMMOTH populations.

Patients in both CARTITUDE-1 populations experienced superior overall response rates and progression-free and overall survival versus patients in the MAMMOTH groups. Among the intent-to-treat and modified intent-to-treat populations, overall response rates were 84% versus 28% and 96% versus 30%, respectively.

Disclosure: For full disclosures of the study authors, visit clinical-lymphoma-myeloma-leukemia.com.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.